Niraparib Tosylate Monohydrate and Abiraterone Acetate
This page contains brief information about niraparib tosylate monohydrate and abiraterone acetate and a collection of links to more information about the use of this drug combination, research results, and ongoing clinical trials.
Use in Cancer
Niraparib tosylate monohydrate and abiraterone acetate is approved to be used with prednisone to treat:
- Prostate cancer that has spread to other parts of the body and is castrate resistant (has not responded to treatments that lower testosterone levels). It is used in adults who have certain mutations in the BRCA1 or BRCA2 gene.
Niraparib tosylate monohydrate and abiraterone acetate is a fixed-dose combination of niraparib tosylate monohydrate and abiraterone acetate. This form may work better than either drug alone. For more information that may apply to these drugs, see the Drug Information Summaries for Niraparib Tosylate Monohydrate and Abiraterone Acetate.
More About Niraparib Tosylate Monohydrate and Abiraterone Acetate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Niraparib Tosylate Monohydrate and Abiraterone Acetate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Niraparib Tosylate Monohydrate And Abiraterone Acetate - Check for trials from NCI's list of cancer clinical trials now accepting patients.